Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 1
1979 1
1981 1
1983 1
1984 2
1985 3
1986 1
1987 1
1988 5
1989 6
1990 7
1991 9
1992 6
1993 5
1994 12
1995 9
1996 13
1997 17
1998 11
1999 21
2000 18
2001 22
2002 27
2003 35
2004 40
2005 64
2006 73
2007 72
2008 61
2009 64
2010 83
2011 116
2012 139
2013 158
2014 188
2015 201
2016 233
2017 266
2018 328
2019 401
2020 520
2021 533
2022 649
2023 675
2024 317

Text availability

Article attribute

Article type

Publication date

Search Results

4,856 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Ye C, Ma Z. Ye C, et al. Arthritis Rheumatol. 2024 Apr;76(4):661-662. doi: 10.1002/art.42771. Epub 2024 Jan 3. Arthritis Rheumatol. 2024. PMID: 38057142 No abstract available.
Reply.
Ye C. Ye C. Arthritis Rheumatol. 2024 Jan 14. doi: 10.1002/art.42796. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 38221744 No abstract available.
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells.
Tsuchida CA, Brandes N, Bueno R, Trinidad M, Mazumder T, Yu B, Hwang B, Chang C, Liu J, Sun Y, Hopkins CR, Parker KR, Qi Y, Hofman L, Satpathy AT, Stadtmauer EA, Cate JHD, Eyquem J, Fraietta JA, June CH, Chang HY, Ye CJ, Doudna JA. Tsuchida CA, et al. Among authors: ye cj. Cell. 2023 Oct 12;186(21):4567-4582.e20. doi: 10.1016/j.cell.2023.08.041. Epub 2023 Oct 3. Cell. 2023. PMID: 37794590 Free PMC article.
SARS-CoV-2 variants evolve convergent strategies to remodel the host response.
Bouhaddou M, Reuschl AK, Polacco BJ, Thorne LG, Ummadi MR, Ye C, Rosales R, Pelin A, Batra J, Jang GM, Xu J, Moen JM, Richards AL, Zhou Y, Harjai B, Stevenson E, Rojc A, Ragazzini R, Whelan MVX, Furnon W, De Lorenzo G, Cowton V, Syed AM, Ciling A, Deutsch N, Pirak D, Dowgier G, Mesner D, Turner JL, McGovern BL, Rodriguez ML, Leiva-Rebollo R, Dunham AS, Zhong X, Eckhardt M, Fossati A, Liotta NF, Kehrer T, Cupic A, Rutkowska M, Mena I, Aslam S, Hoffert A, Foussard H, Olwal CO, Huang W, Zwaka T, Pham J, Lyons M, Donohue L, Griffin A, Nugent R, Holden K, Deans R, Aviles P, Lopez-Martin JA, Jimeno JM, Obernier K, Fabius JM, Soucheray M, Hüttenhain R, Jungreis I, Kellis M, Echeverria I, Verba K, Bonfanti P, Beltrao P, Sharan R, Doudna JA, Martinez-Sobrido L, Patel AH, Palmarini M, Miorin L, White K, Swaney DL, Garcia-Sastre A, Jolly C, Zuliani-Alvarez L, Towers GJ, Krogan NJ. Bouhaddou M, et al. Among authors: ye c. Cell. 2023 Oct 12;186(21):4597-4614.e26. doi: 10.1016/j.cell.2023.08.026. Epub 2023 Sep 21. Cell. 2023. PMID: 37738970
Base-editing mutagenesis maps alleles to tune human T cell functions.
Schmidt R, Ward CC, Dajani R, Armour-Garb Z, Ota M, Allain V, Hernandez R, Layeghi M, Xing G, Goudy L, Dorovskyi D, Wang C, Chen YY, Ye CJ, Shy BR, Gilbert LA, Eyquem J, Pritchard JK, Dodgson SE, Marson A. Schmidt R, et al. Among authors: ye cj. Nature. 2024 Jan;625(7996):805-812. doi: 10.1038/s41586-023-06835-6. Epub 2023 Dec 13. Nature. 2024. PMID: 38093011
Functional characterization of Alzheimer's disease genetic variants in microglia.
Yang X, Wen J, Yang H, Jones IR, Zhu X, Liu W, Li B, Clelland CD, Luo W, Wong MY, Ren X, Cui X, Song M, Liu H, Chen C, Eng N, Ravichandran M, Sun Y, Lee D, Van Buren E, Jiang MZ, Chan CSY, Ye CJ, Perera RM, Gan L, Li Y, Shen Y. Yang X, et al. Among authors: ye cj. Nat Genet. 2023 Oct;55(10):1735-1744. doi: 10.1038/s41588-023-01506-8. Epub 2023 Sep 21. Nat Genet. 2023. PMID: 37735198 Free PMC article.
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Liu H, Cheng Y, Cheng J, Wang X, Nie J, Yang J, Wu X, Wang X, Li H, Ye C, Dong F, Wu S, Zhu X, Xu B; PHILA Investigators. Ma F, et al. Among authors: ye c. BMJ. 2023 Oct 31;383:e076065. doi: 10.1136/bmj-2023-076065. BMJ. 2023. PMID: 37907210 Free PMC article. Clinical Trial.
4,856 results